We read with great interest the recent study by Gilliam-Vigh et al demonstrating significant transcriptomic alterations in the intestinal mucosa of individuals with type 2 diabetes (T2D), particularly increased immune activation, altered barrier function in the large intestine and metabolic dysfunction. 1 These findings provide crucial mechanistic insights that complement observations on metabolic disturbances in patients with irritable bowel syndrome (IBS), supporting the rationale for glucose-targeted interventions.
Personalised low-glycaemic diet: a novel therapeutic approach Given the substantial interindividual variability in glycaemic responses, 2 we investigated the therapeutic potential of a personalised low-glycaemic diet (PLGD) in IBS management. In our nutritional observation study of 20 age and gender-matched patients with IBS, we compared clinical outcomes between those receiving either a PLGD or the established low-FODMAP diet (LFD) over a minimum 3-month period ( figure 1 ).
Remarkably, our personalised nutrition (PN) approach achieved symptom improvement comparable to...
Gut (BMJ) published a clinical update in Research Highlights on 07 Apr 2026.
The item focuses on Impaired glucose metabolism in irritable bowel syndrome: personalised low-glycaemic diet as potential therapeutic target.
Review the original article for the full source wording and details.